Actively Recruiting
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study
Led by Wonju Severance Christian Hospital · Updated on 2024-07-30
100
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Comparison nafamostat and low molecular weight heparin among dialysis patients
CONDITIONS
Official Title
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Platelet count below 10,000
- Partial thromboplastin time (PTT) above 60 seconds
- International normalized ratio (INR) above 20
- Patients with bleeding such as epistaxis, orbital bleeding, or hematuria
- Recent brain hemorrhage within the past 6 months
- Receiving anticoagulant therapy (coumadin or NOAC)
- Using dual antiplatelet agents
- Received major surgery within the past one month
You will not qualify if you...
- Current cancer
- Liver cirrhosis
- Pregnancy
- Drug allergy
- Current bleeding on a major organ such as brain or gastrointestinal tract
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yonsei Unviersity Wonju College of Medicin
Wŏnju, Kangwondo, South Korea, 26426
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here